Taysha Gene Therapies (NASDAQ: TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for CNS diseases, has granted a stock option to a new employee. The Compensation Committee approved an option to purchase 45,000 shares of common stock under the company's 2023 Inducement Plan. The option has an exercise price of $2.41, matching the closing price on the grant date. The stock option features a 10-year term with a four-year vesting schedule: 25% vests after the first year, followed by monthly vesting of the remaining 75% over 36 months. The grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Taysha Gene Therapies (NASDAQ: TSHA), una società biotecnologica in fase clinica specializzata in terapie geniche basate su AAV per malattie del sistema nervoso centrale, ha concesso un'opzione su azioni a un nuovo dipendente. Il Comitato per la Remunerazione ha approvato un'opzione per l'acquisto di 45.000 azioni ordinarie nell'ambito del Piano di Incentivazione 2023 della società. L'opzione ha un prezzo di esercizio di 2,41 $, pari al prezzo di chiusura del giorno della concessione. L'opzione su azioni ha una durata di 10 anni con un piano di maturazione quadriennale: il 25% matura dopo il primo anno, seguito da una maturazione mensile del restante 75% nei successivi 36 mesi. La concessione è stata effettuata in conformità alla Regola di Quotazione Nasdaq 5635(c)(4) come incentivo all'assunzione.
Taysha Gene Therapies (NASDAQ: TSHA), una empresa biotecnológica en etapa clínica especializada en terapias génicas basadas en AAV para enfermedades del sistema nervioso central, ha otorgado una opción sobre acciones a un nuevo empleado. El Comité de Compensación aprobó una opción para comprar 45,000 acciones ordinarias bajo el Plan de Incentivos 2023 de la compañía. La opción tiene un precio de ejercicio de $2.41, que coincide con el precio de cierre en la fecha de concesión. La opción sobre acciones tiene un plazo de 10 años con un calendario de adquisición de derechos de cuatro años: el 25% se adquiere después del primer año, seguido por una adquisición mensual del 75% restante durante 36 meses. La concesión se realizó conforme a la Norma de Cotización Nasdaq 5635(c)(4) como incentivo laboral.
Taysha Gene Therapies (NASDAQ: TSHA)는 중추신경계 질환을 위한 AAV 기반 유전자 치료제에 특화된 임상 단계 바이오테크 회사로, 신입 직원에게 주식 매수 선택권을 부여했습니다. 보상 위원회는 회사의 2023년 유인 계획에 따라 45,000주의 보통주 매수 옵션을 승인했습니다. 이 옵션의 행사가격은 $2.41로, 부여일 종가와 동일합니다. 주식 옵션은 10년 기간이며 4년 베스팅 스케줄을 따릅니다: 첫 해 후 25%가 베스팅되고, 이후 36개월 동안 나머지 75%가 매월 베스팅됩니다. 이 부여는 고용 유인책으로서 나스닥 상장 규칙 5635(c)(4)에 따라 이루어졌습니다.
Taysha Gene Therapies (NASDAQ : TSHA), une société biotechnologique en phase clinique spécialisée dans les thérapies géniques à base d'AAV pour les maladies du système nerveux central, a accordé une option d'achat d'actions à un nouvel employé. Le comité de rémunération a approuvé une option d'achat de 45 000 actions ordinaires dans le cadre du plan d'incitation 2023 de la société. L'option présente un prix d'exercice de 2,41 $, correspondant au cours de clôture à la date d'attribution. L'option d'achat d'actions a une durée de 10 ans avec un calendrier d'acquisition sur quatre ans : 25 % acquises après la première année, suivies d'une acquisition mensuelle des 75 % restants sur 36 mois. L'attribution a été effectuée conformément à la règle de cotation Nasdaq 5635(c)(4) en tant qu'incitation à l'embauche.
Taysha Gene Therapies (NASDAQ: TSHA), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf AAV-basierte Gentherapien für Erkrankungen des Zentralnervensystems spezialisiert hat, hat einem neuen Mitarbeiter eine Aktienoption gewährt. Der Vergütungsausschuss genehmigte eine Option zum Kauf von 45.000 Stammaktien im Rahmen des Inducement-Plans 2023 des Unternehmens. Der Ausübungspreis beträgt 2,41 $ und entspricht dem Schlusskurs am Tag der Gewährung. Die Aktienoption hat eine Laufzeit von 10 Jahren mit einem vierjährigen Vesting-Zeitplan: 25 % werden nach dem ersten Jahr fällig, gefolgt von monatlicher Vesting der verbleibenden 75 % über 36 Monate. Die Gewährung erfolgte gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Anreiz zur Einstellung.
Positive
None.
Negative
None.
DALLAS, May 02, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on May 1, 2025, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 45,000 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has an exercise price of $2.41 which is equal to the closing price of Taysha's common stock on the date of grant. The stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of the stock option is subject to such employee's continued service to Taysha on each vesting date.
About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.
Company Contact: Hayleigh Collins Senior Director, Corporate Communications and Investor Relations Taysha Gene Therapies, Inc. hcollins@tayshagtx.com
What stock options did TSHA grant to its new employee in May 2025?
TSHA granted one new employee an option to purchase 45,000 shares of common stock at an exercise price of $2.41 per share, with a 10-year term and four-year vesting schedule.
What is the vesting schedule for Taysha Gene Therapies' May 2025 stock option grant?
The stock option vests over 4 years, with 25% vesting after the first year and the remaining 75% vesting in equal monthly installments over the following 36 months.
What is Taysha Gene Therapies' 2023 Inducement Plan?
The 2023 Inducement Plan is used by Taysha to grant stock options as employment inducements to new employees, in accordance with Nasdaq Listing Rule 5635(c)(4).
What is Taysha Gene Therapies' main business focus?
Taysha is a clinical-stage biotechnology company focused on developing AAV-based gene therapies for severe monogenic diseases of the central nervous system (CNS).
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
